Quick Answer
TREACE MEDICAL CONCEPTS, INC. reported Diluted EPS of $0.93 per share (loss) for fiscal year 2025.
TREACE MEDICAL CONCEPTS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.93 | -3.3% |
| 2024 | -$0.90 | -11.1% |
| 2023 | -$0.81 | -5.2% |
| 2022 | -$0.77 | -79.1% |
| 2021 | -$0.43 | -258.3% |
| 2020 | -$0.12 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.26 | -4.0% | +7.1% |
| June 30, 2025 | -$0.28 | +17.6% | -12.0% |
| March 31, 2025 | -$0.25 | +16.7% | +0.0% |
| September 30, 2024 | -$0.25 | +10.7% | +26.5% |
| June 30, 2024 | -$0.34 | -70.0% | -13.3% |
| March 31, 2024 | -$0.30 | -30.4% | -7.1% |
| September 30, 2023 | -$0.28 | -27.3% | -40.0% |
| June 30, 2023 | -$0.20 | +35.5% | +13.0% |
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -3.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, TREACE MEDICAL CONCEPTS, INC.’s diluted eps has declined by 675.0% (from $0.12 per share (loss) to $0.93 per share (loss)).
- The most recent figure is from TREACE MEDICAL CONCEPTS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: